Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls
Stifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.
How this was made
The 30-second read
Why it matters
Collectively, the changes could shift short-term sentiment and influence price targets.
Market read
The breadth of analyst actions suggests a modest shift in market sentiment across tech, biotech, and industrial sectors.
What to watch
Potential earnings volatility and regulatory risks not addressed.
Background
Analyst firms issued multiple upgrades, downgrades, and new coverage across various sectors.
Ticker impact
Stifel upgraded Microsoft to Buy with a $575 price target, citing stronger revenue growth and LLM strategy.
Bullish, price may rise toward target.
Upgrade and higher target suggest improved outlook.
Susquehanna upgraded RXO to Neutral, lowering target to $19 after share pullback and better operating trends.
Limited move, possible modest decline.
Downgrade and lower target reduce bullish pressure.
JPMorgan upgraded Graphic Packaging to Overweight with a $11.50 target despite a murky pricing environment.
Potential modest gain.
Improved risk/reward perception.
RBC Capital upgraded Lakefront Biotherapeutics to Outperform, raising target to $45 on rare disease opportunity.
Likely upside.
Therapeutic potential cited.
Guggenheim upgraded Editas Medicine to Buy with a $5 target, pending clinical data on EDIT-401.
Potential rise if data confirms.
Positive outlook tied to upcoming data.
Wedbush downgraded Compass Therapeutics to Neutral, noting FDA trial requirement before BLA.
Possible decline.
Regulatory hurdle highlighted.
Wolfe Research downgraded Autoliv to Peer Perform, citing a challenging 2027 growth outlook.
Potential modest drop.
Growth concerns noted.
UBS downgraded PG&E to Neutral from Buy, cutting target to $14 over wildfire liability risk.
Likely downside.
Regulatory risk emphasized.
Market effects
Broad analyst upgrades may lift tech and biotech sentiment.
US equity markets may see modest positive bias.
Limited to US-listed issuers.
Counterpoint
Some upgrades may be premature given macro uncertainties.
Key entities
- AnalystStifel
Upgraded Microsoft
- AnalystSusquehanna
Upgraded RXO
- AnalystJPMorgan
Upgraded Graphic Packaging
- AnalystRBC Capital
Upgraded Lakefront Biotherapeutics
- AnalystGuggenheim
Upgraded Editas Medicine
